Cured by Innovaccer’s Post

Healthcare evolves and innovates rapidly, and it can be challenging to cut through the noise and find relevant signals that inform the right action.     Today, we're announcing the launch of IRIS, the first insights-as-a-service platform designed to help industry leaders act with clarity and confidence when transformative #healthcare market events emerge — like we're seeing right now with GLP-1 agonists and obesity treatment.     Fueled by the analysis of billions of data points using our proprietary AI, IRIS offers a live dashboard and timely market-view reports to help leaders understand and navigate the rapidly evolving obesity and GLP-1 landscape.      Our first report dives deeper into the unprecedented impact of new "GLP-1 influencers" with online behaviors and monetization strategies that resemble beauty and fashion influencers more than the traditional healthcare social figures.     Learn how we're providing our clients and the healthcare industry with insights into what's happening now and the forces that could shape what's coming next: https://bit.ly/3wp8D0d

If you believe #GLP-1 agonists for #obesity treatment are just another class of #pharma products, you’re wrong. This market is unfolding like nothing we’ve seen in healthcare before. That means the strategies we’ve traditionally used to approach market access, brand marketing, corporate affairs and brand communications, medical affairs and everything else we do in #healthcare may not apply here.    Real Chemistry’s first market-view report, titled “GLP-1 Agonists: Signals of a New Era,” underscores this reality… 💡 There’s a new “GLP-1 influencer” in town with online behaviors, content creation momentum and monetization approaches that mirror what has been seen with the beauty and fashion influencer community, rather than with healthcare influencers. This new phenomenon is putting additional strain on an already complex patient-healthcare provider relationship and creating pressure for marketing and communication teams to create new ways to engage, educate and activate.   💡 Growing consumer-led, online communities are joining forces to navigate and advise others on managing market impacts, such as shortages and access. As a result, these communities are circumventing the traditional ecosystem, creating gaps in real-world data visibility and adversely impacting the healthcare provider-patient relationship.   💡 Currently, there are 119 active GLP-1 agonist clinical trials, with 53 in Phases 3 or 4. These trials cover more than 60 potential new disease states for GLP-1 treatment. The potential market entry of new drugs in five to 10 years means that organizations that are exploring launching new products will need stronger commercial readiness strategies to optimize their potential position with investors.   Leaders, brand planning season is upon us. How are you preparing for the impacts this market will have on your #business? Send me a message or comment here.    IRIS has the insights into what's happening now and the forces that could shape what's coming next: https://bit.ly/3wp8D0d. It’s time to see. #glp1s #healthcareinsights #marketintelligence #research #brandstrategy #planning #realchemistry

As we all monitor, fascinate, explore and wonder this new class of obesity drugs, GLP-1s, check our our first report about social influencers in that space as well as our new AI generated dashboard - IRIS. Fueled by the analysis of billions of data points using our proprietary AI, IRIS offers a live dashboard and timely market-view reports to help leaders understand and navigate the rapidly evolving obesity and GLP-1 landscape. @realchemistry

Stop relying on cookies, lookalikes, and other imprecise physician audiences! Reach your exact, full NPI list with 1:1 targeting from their home to the clinic – for the consistency and precision that drives brand conversion. Learn more: https://bit.ly/3YjfnZ9

Our contextual targeting engine has been enhanced by adding keyword hierarchies assisted with AI. Diabetes for example is a common word which appears in articles that are not really focused on diabetes but something else. But if the article contains dozens of secondary keywords like A1C, insulin resistance, hyperglycemia, Metformin and dozens more, the article is far more likely to focus on managing and treating diabetes and therefore more likely to be read by someone that has been diagnosed with diabetes. Bottom line, we all understand the more nuanced the keywords that are part of the page, the more focused the content and the more qualified the user and the higher their intent. #healthcaremarketing #pharmamarketing

Our first webinar in a multi-part series about the 7 key dimensions for brand launch success will be happening at noon today. If you're interested in learning from Dan Callahan, leader of ZoomRx Brand Builder, who has more than 25 years of expertise helping #biopharma brands launch, click on the following registration link: https://lnkd.in/dJ3w-a2S #brandbuilding #branding #launch #launchmarketing #marketinsights #marketresearch #marketingwebinar #pharma #biotech

Take some time Tuesday at Noon to hear Dan Callahan begin our 7-part PHYCURE webinar series. Tomorrow's webinar will focus on Patient Targeting research for biopharma launch. Each month, there will be a new webinar each month addressing a new dimension of the #PHYCURE framework for launch success. #marketresearch #marketinsights #pharma #pharmamarketing #biopharma #biopharmabranding #brandingstrategy #branding

Brand Analytics can help you by: 🎯 Targeting the right HCPs: Find the doctors most likely to prescribe your brand. 📊 Crafting data-driven strategies: Create messaging that clicks with each segment. 🕵️♂️ Outmaneuver competitors: Spot their strengths and make your brand shine. 📈 Measuring success: Track key metrics and fine-tune your sales force for maximum impact. Empower your sales team and boost your performance with Brand Analytics. Curious about how it can transform your SFE strategy? Let's Connect!👇 https://hubs.li/Q02P-1-T0 #SalesForceEffectiveness #SFE #SalesReps #BrandAnalytics

Traditional HCP advertising is limited by one-size-fits-all targeting, ignores patients, and uses fragmented data sources that fail to produce strategic actionable insights. Watch Katie Carr's full #DPE24 presentation to learn more about solving the complexities of #OmnichannelMarketing with an AI-driven approach: https://lnkd.in/eddFeAVh Digital Pharma Series

Have you ever wondered why understanding actual behaviors vs. stated preferences is crucial in market research? 🤔 At Qrious Insight, we're all about delving into observed actions. Why? Because actions inherently carry a volume that words can seldom match. At Qrious Insight, our meticulously crafted solutions are designed to sharpen your research accuracy by prioritizing real-world behaviors. This approach not only refines your targeting but also ensures the insights you gain are authentic and actionable. Discover how behavioral targeting can transform the accuracy of your sample. Ready to see the difference? Let's chat. https://lnkd.in/efP5VftP #BehavioralInsights #MarketResearch #QriousInsight